Individualised incretin-based treatment for type 2 diabetes
- PMID: 20580425
- DOI: 10.1016/S0140-6736(10)60998-1
Individualised incretin-based treatment for type 2 diabetes
Comment on
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.Lancet. 2010 Aug 7;376(9739):431-9. doi: 10.1016/S0140-6736(10)60590-9. Epub 2010 Jun 26. Lancet. 2010. PMID: 20580422 Clinical Trial.
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.Lancet. 2010 Jun 26;375(9733):2234-43. doi: 10.1016/S0140-6736(10)60406-0. Lancet. 2010. PMID: 20609969 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
